Express Sword refers to many diseases such as diabetes, NASH, heart failure, etc. Xin Rui aims to improve cell metabolism

▎Editor of WuXi AppTec's content team On July 20, 2021, Rivus Pharmaceuticals announced the completion of a US$35 million Series A financing
.

The funds obtained will be used to advance the development of potential "first-in-class" oral small molecule drugs-"Controlled Metabolic Accelerators" (CMAs), which aims to use the body's natural processes to improve cell metabolism and treat the heart The internal causes of vascular metabolic diseases
.

Its early clinical results show that CMAs have great potential to fundamentally change the treatment landscape for the treatment of chronic diseases related to metabolic health
.

The initial project of the pipeline will focus on a series of metabolic related diseases, including type 2 diabetes, severe hypertriglyceridemia (SHTG), non-alcoholic steatohepatitis (NASH), and cardiovascular diseases such as ejection fraction preservation Type heart failure (HFpEF)
.

CMAs is an innovative method that activates mitochondrial uncoupling to a limited extent.
Mitochondrial uncoupling is a natural process by which the body regulates and consumes energy
.

By transporting protons from the mitochondrial membrane space, CMAs can promote the increase of sugar and fat oxidation while maintaining the level of adenosine triphosphate (ATP) production
.

Activating this process will reduce fat accumulation and prevent extra fat accumulation throughout the body
.

▲CMAs can promote the increase of sugar and fat oxidation while maintaining the same level of ATP production (picture source: Rivus official website) Rivus is currently conducting a phase 2a clinical trial of its flagship drug HU6, which will be used in specific metabolic cardiovascular In patients with disease, evaluate the efficacy and safety of HU6
.

HU6 has completed a phase 1 trial, and the results of the trial have shown that it has an early positive effect on key metabolic parameters and is well tolerated
.

"Cardiovascular and metabolic-related diseases can have a negative impact on the health and quality of life of patients, and place a significant burden on the medical system
.

Many existing treatment options target the downstream effects of metabolic diseases, but they rarely target diseases.
The internal reason for this
.

" Rivus President and CEO Allen Cunningham explained, "Patients’ energy intake exceeds the body’s needs.
Over time, this will lead to inefficiency of cell metabolism and excessive accumulation of fat
.

We design The CMAs are designed to effectively target the root causes of these diseases by improving cell metabolism, and it is possible to halt or even reverse these diseases
.

"Reference: [1] Rivus Pharmaceuticals Launches with $35 Million Series A Financing to Develop Novel Treatments for Cardio-Metabolic Diseases.
Retrieved July 20, 2021, from https:// -launches-with-35-million-series-a-financing-to-develop-novel-treatments-for-cardio-metabolic-diseases-301336574.
html[2] Rivus' fat-trimming therapy nabs $35M to harness our own biology against a host of diseases.
Retrieved July 20, 2021, from https:// own-biology-against-a-host[3] Can a next-gen take on a deadly weight loss pill conquer cardiometabolic diseases? A Medicxi-backed startup thinks so.
Retrieved July 20, 2021, from https://endpts.
com/can-a-next-gen-take-on-a-deadly-weight-loss-pill-conquer-cardiometabolic-disease-a-medicxi-backed-startup-thinks-so/ Note: This article aims to introduce medicine and health Research progress, not a treatment plan recommendation
.

If you need guidance on treatment plans, please go to a regular hospital for treatment
.